Pharmacological inhibition of the transcription factor PU.1 in leukemia
Open accessThe DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
The transcription factor PU.1 is often impaired in patients with acute myeloid leukemia (AML). Here, we used AML cells that already had low PU.1 levels and further inhibited PU.1 using either RNA interference or, to our knowledge, first-in-class small-molecule inhibitors of PU.1 that we developed specifically to allosterically interfere with PU.1-chromatin binding through interaction with the DNA minor groove that flanks PU.1-binding motifs. These small molecules of the heterocyclic diamidine family disrupted the interaction of PU.1 with target gene promoters and led to downregulation of canonical PU.1 transcriptional targets. shRNA or small-molecule inhibition of PU.1 in AML cells from either PU.1lo mutant mice or human patients with AML-inhibited cell growth and clonogenicity and induced apoptosis. In murine and human AML (xeno)transplantation models, treatment with our PU.1 inhibitors decreased tumor burden and resulted in increased survival. Thus, our study provides proof of concept that PU.1 inhibition has potential as a therapeutic strategy for the treatment of AML and for the development of small-molecule inhibitors of PU.1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“A very intriguing new prospect for fast antagonism of PU.1 activity is the discovery of small-molecule inhibitors, some of which are highly potent and specific at blocking PU.1 action in leukemia cells; however, these have not yet been tested for effects on normal T-cell development (89).”
From Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development (2019) · cites this paper as [89]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“a luminescence reduction of 11.8 ± 22.3% in the presence of the PU.1-motif intercalator DB2313 (Antony-Debré et al., 2017; Munde et al., 2014; P ≤ 0.0001; Table S5).”
From A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation (2023) · cites this paper as Antony-Debré et al., 2017
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 2×
“was performed with gene sets from the Molecular Signatures Database (56, 57) and from the PU.”
MethodGenomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Margolin, A. A., Nemenman, I., Basso, K., Wiggins, C., Stolovitzky, G., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-s1-s7 · Cited by 2,420
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, M., Bamford, S., Cole, C., Ward, S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1075 · Cited by 2,283
Margolin, A. A., Nemenman, I. M., Basso, K., Wiggins, C. H., Stolovitzky, G. A., Favera, R. D., & Califano, A. (2006) · BMC Bioinformatics · doi:10.7916/d8g15zbp · Cited by 2,246
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages
Scott, E. W., Simon, M. C., Anastasi, J., & Singh, H. (1994) · Science · doi:10.1126/science.8079170 · Cited by 1,532 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
BackgroundReverse engineering of regulatory networks in human B cells
Basso, K., Margolin, A. A., Stolovitzky, G., Klein, U., Dalla-Favera, R., & Califano, A. (2005) · Nature Genetics · doi:10.1038/ng1532 · Cited by 1,404
Kim, J. H., Lee, S.-R., Li, L.-H., Park, H.-J., Park, J.-H., Lee, K. Y., Kim, M.-K., Shin, B. A., & Choi, S.-Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018556 · Cited by 1,338 · cited 1×
“was linked by a sequence encoding a self-cleaving 2A peptide (53).”
BackgroundTargeted disruption of the PU.1 gene results in multiple hematopoietic abnormalities
McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00949.x · Cited by 1,130 · cited 1×
“1 is important for myeloid and lymphoid differentiation (13, 14), as well as hematopoietic stem cell (HSC) maintenance (15, 16).”
Background
Research works printed but not linked: 1
- Nanjunda RM, Munde M, Liu M, Wilson WD. Real-time monitoring of nucleic acid interactions with biosensor surface plasmon resonance. In: Wanunu Y, ed. Methods for Studying DNA/ Drug Interactions. Boca Raton, FL: CRC Press; 2011:92-122.
Cited by
Targeting transcription factors in cancer — from undruggable to reality
Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919
Targeting Transcription Factors for Cancer Treatment
Lambert, M., Jambon, S., Depauw, S., & David-Cordonnier, M.-H. (2018) · Molecules · doi:10.3390/molecules23061479 · Cited by 352
PTEN Tumor-Suppressor: The Dam of Stemness in Cancer
Luongo, F., Colonna, F., Calapà, F., Vitale, S., Fiori, M. E., & De Maria, R. (2019) · Cancers · doi:10.3390/cancers11081076 · Cited by 189
“Of note, replacing rapamycin, with NVP-BEZ235, a dual inhibitor of PI3K and mTOR, resulted in cell cycle arrest and reduced L-CSCs compartment [186].”
BackgroundInfluentialViny, A. D., Bowman, R. L., Liu, Y., Lavallée, V.-P., Eisman, S. E., Xiao, W., Durham, B. H., Navitski, A., Park, J., Braunstein, S., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.003 · Cited by 158
“role in determining hematopoietic lineage commitment (Antony-Debre et al., 2017; Will et al., 2015).”
An overview of recent advances in duplex DNA recognition by small molecules
Bhaduri, S., Ranjan, N., & Arya, D. P. (2018) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.14.93 · Cited by 162
Mysore, V., Cullere, X., Mears, J., Rosetti, F., Okubo, K., Liew, P. X., Zhang, F., Madera-Salcedo, I., Rosenbauer, F., Stone, R. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24591-x · Cited by 125
Transcriptional, Epigenetic and Metabolic Programming of Tumor-Associated Macrophages
Larionova, I., Kazakova, E., Patysheva, M. R., & Kzhyshkowska, J. G. (2020) · Cancers · doi:10.3390/cancers12061411 · Cited by 140
“1 promotes macrophage differentiation toward alternatively activated macrophages and is involved in the development of many types of tumors including breast cancer [67], myeloma [68], acute myeloid leukemia [69], glioma [70] and hepatocellular carcinoma [71].”
BackgroundLau, S.-F., Chen, C., Fu, W.-Y., Qu, J. Y., Cheung, T. H., Fu, A. K. Y., & Ip, N. Y. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107530 · Cited by 114
“1-DNA interaction (Antony-Debré et al., 2017), before injecting IL-33.”
BackgroundNafie, M. S., Arafa, K. K., Sedky, N. K., Alakhdar, A. A., & Arafa, R. K. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109087 · Cited by 104
Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development
Rothenberg, E. V., Hosokawa, H., & Ungerbäck, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00228 · Cited by 99
“1 action in leukemia cells; however, these have not yet been tested for effects on normal T-cell development (89).”
BackgroundRecent developments in compounds acting in the DNA minor groove
Rahman, A., O'Sullivan, P. J., & Rozas, I. (2019) · MedChemComm · doi:10.1039/c8md00425k · Cited by 100
Neurofibromin and suppression of tumorigenesis: beyond the GAP
Mo, J., Moye, S. L., McKay, R. M., & Le, L. Q. (2022) · Oncogene · doi:10.1038/s41388-021-02156-y · Cited by 100
“While typically considered “undruggable”, various strategies are now being used to target transcription factors: (1) Compounds that bind to the DNA minor groove of target gene promoter sequences and disrupt transcription factor-DNA binding have been developed [115, 252].”
BackgroundETS transcription factors as emerging drug targets in cancer
Hsing, M., Wang, Y. Z., Rennie, P. S., Cox, M., & Cherkasov, A. R. (2019) · Medicinal Research Reviews · doi:10.1002/med.21575 · Cited by 100
“1 expression or activity is present.(48) While overexpression of PU.”
BackgroundInfluentialTu, J., Chen, W., Fang, Y., Han, D., Chen, Y., Jiang, H., Tan, X., Xu, Z., Wu, X., Wang, H., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222708 · Cited by 70
Zhang, S., Zhao, S., Qi, Y., Li, B., Wang, H., Pan, Z., Xue, H., Jin, C., Qiu, W., Chen, Z., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.035 · Cited by 68
“Chromatin immunoprecipitation ChIP assays were performed using a ChIP kit from Merck Millipore (17-295) according to the manufacturer’s instructions.”
MethodHernandez, G., Mills, T. S., Rabe, J. L., Chavez, J. S., Kuldanek, S., Kirkpatrick, G., Noetzli, L., Jubair, W. K., Zanche, M., Myers, J. R., et al. (2020) · Haematologica · doi:10.3324/haematol.2018.197210 · Cited by 58
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 69
Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
Thakurta, A., Pierceall, W. E., Amatangelo, M. D., Flynt, E., & Agarwal, A. (2021) · Oncotarget · doi:10.18632/oncotarget.27973 · Cited by 66
“com expression by IMiD agents led to arrest in megakaryocyte precursors impacting thrombocytopenia [42, 43].”
BackgroundInhibition of PU.1 ameliorates metabolic dysfunction and non-alcoholic steatohepatitis
Liu, Q., Yu, J., Wang, L., Tang, Y., Zhou, Q., Ji, S., Wang, Y., Santos, L., Haeusler, R. A., Que, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.02.025 · Cited by 51
Nowak, J. K., Adams, A. T., Kalla, R., Lindstrøm, J. C., Vatn, S., Bergemalm, D., Keita, Å. V., Gomollón, F., Jahnsen, J., Vatn, M. H., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac033 · Cited by 51
Targetable leukaemia dependency on noncanonical PI3Kγ signalling
Luo, Q., Raulston, E. G., Prado, M. A., Wu, X., Gritsman, K., Whalen, K. S., Yan, K., Booth, C. A. G., Xu, R., van Galen, P., et al. (2024) · Nature · doi:10.1038/s41586-024-07410-3 · Cited by 53
Chambers, C., Čermáková, K., Chan, Y. S., Kurtz, K. J., Wohlan, K., Lewis, A. H., Wang, C., Pham, A., Dejmek, M., Šála, M., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-2129 · Cited by 57
“Here, we demonstrate that transient SWI/SNF inhibition dysregulates hematopoietic development within BM, with lineage-speci fi c effects similar to PU.1 inhibition, which also impacts committed PU.1-dependent lineages but spares HSCs (47).”
InfluentialTargeting transcription factors in acute myeloid leukemia
Takei, H., & Kobayashi, S. S. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2488-1 · Cited by 53
Long, L., Assaraf, Y. G., Lei, Z., Peng, H., Yang, L., Chen, Z., & Ren, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100703 · Cited by 50
Depauw, S., Lambert, M., Jambon, S., Paul, A., Peixoto, P., Nhili, R., Marongiu, L., Figeac, M., Dassi, C., Paul-Constant, C., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01448 · Cited by 47
Self-citationThoms, J. A. I., Truong, P., Subramanian, S., Knezevic, K., Harvey, G., Huang, Y., Seneviratne, J. A., Carter, D. R., Joshi, S. M., Skhinas, J. N., et al. (2021) · Blood · doi:10.1182/blood.2020009707 · Cited by 45
Aznaourova, M., Schmerer, N., Janga, H., Zhang, Z., Pauck, K., Bushe, J., Volkers, S. M., Wendisch, D., Georg, P., Ntini, E., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120680119 · Cited by 43
T-ALL leukemia stem cell 'stemness' is epigenetically controlled by the master regulator SPI1
Zhu, H., Zhang, L., Wu, Y., Dong, B., Guo, W., Wang, M., Yang, L., Fan, X., Tang, Y., Liu, N., et al. (2018) · eLife · doi:10.7554/elife.38314 · Cited by 42
“, 2012), at nanomolar concentrations (Antony-Debré et al., 2017).”
BackgroundMethodPaul, A., Guo, P., Boykin, D. W., & Wilson, W. D. (2019) · Molecules · doi:10.3390/molecules24050946 · Cited by 36
“The latter are well studied in the field of AT sequence-specific DNA minor groove binders which have been shown to exhibit excellent nuclear uptake and transcription factor inhibitory activity [82].”
BackgroundSelf-citationCompound Shape Effects in Minor Groove Binding Affinity and Specificity for Mixed Sequence DNA
Guo, P., Farahat, A. A., Paul, A., Harika, N. K., Boykin, D. W., & Wilson, W. D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08152 · Cited by 36
Self-citationGSK-3: a multifaceted player in acute leukemias
Martelli, A. M., Evangelisti, C., Paganelli, F., Chiarini, F., & McCubrey, J. A. (2021) · Leukemia · doi:10.1038/s41375-021-01243-z · Cited by 40
“Interestingly, more than 40% of AML patients display low PU-1 expression [70], while an 80% reduction of PU.”
BackgroundRao, S., Han, A., Zukowski, A., Kopin, E. G., Sartorius, C. A., Kabos, P., & Ramachandran, S. (2022) · Science Advances · doi:10.1126/sciadv.abm4358 · Cited by 41
PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells
Hu, T., Morita, K., Hill, M. C., Jiang, Y., Kitano, A., Saito, Y., Wang, F., Mao, X., Hoegenauer, K. A., Morishita, K., et al. (2019) · Blood · doi:10.1182/blood.2018888255 · Cited by 33
Transcriptional networks in acute myeloid leukemia
Thoms, J. A. I., Beck, D., & Pimanda, J. E. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22794 · Cited by 34
Control of ribosomal RNA synthesis by hematopoietic transcription factors
Charles Antony, A., George, S. S., Blum, J., Somers, P., Thorsheim, C. L., Wu-Corts, D. J., Ai, Y., Gao, L., Lv, K., Tremblay, M. G., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.08.027 · Cited by 36
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor
Zhu, Y., Lu, L., Qiao, C., Shan, Y., Li, H., Qian, S., Hong, M., Zhao, H., Li, J., Yang, Z., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0157-8 · Cited by 32
“1 activity was developed as a therapeutic strategy in AML recently [44].”
BackgroundAirway and parenchymal transcriptomics in a novel model of asthma and COPD overlap
Tu, X., Kim, R., Brown, A. C., de Jong, E., Jones, B., Ali, M. K., Gomez, H. M., Budden, K. F., Starkey, M. R., Cameron, G. J. M., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.04.032 · Cited by 32
Han, R., Yuan, T., Yang, Z. H., Zhang, Q., Wang, W., Lin, L., Zhu, M.-Q., & Gao, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105345 · Cited by 32
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
“One described molecules that inter-calate into the DNA at PU.1 motifs and show therapeutic potential in models of leukemia (Antony-Debr´e et al., 2017) and fibrosis (Wohlfahrt et al., 2019).”
InfluentialIntrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1
Xhani, S., Lee, S., Kim, H. M., Wang, S., Esaki, S., Ha, V. L., Khanezarrin, M., Fernandez, G. L., Albrecht, A. V., Aramini, J. M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay3178 · Cited by 36
Self-citationHu, S., Zhang, F., Wang, J., Zhang, J., Li, C., Lyu, Y., Wang, Y., Huang, R., Gao, Y., Yang, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415205 · Cited by 46
Martin-Estebane, M., & Gomez-Nicola, D. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00149 · Cited by 25
Kim, H., Perovanović, J., Shakya, A., Shen, Z., German, C. N., Ibarra, A., Jafek, J. L., Lin, N.-P., Evavold, B. D., Chou, D. H., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20200533 · Cited by 25
Self-citationParadoxical Role of AT-rich Interactive Domain 1A in Restraining Pancreatic Carcinogenesis
Ferri-Borgogno, S., Barui, S., McGee, A. M., Griffiths, T., Singh, P. K., Piett, C. G., Ghosh, B., Bhattacharyya, S., Singhi, A., Pradhan, K., et al. (2020) · Cancers · doi:10.3390/cancers12092695 · Cited by 22
“1-chromatin binding [30], we found “KAC” cells were significantly more sensitive to growth inhibition, compared to control “KC” and “KPC” cells (Figure 7J), presenting PU.”
ResultSelf-citationTaylor, S. J., Stauber, J., Bohorquez, O., Tatsumi, G., Kumari, R., Chakraborty, J., Bartholdy, B. A., Schwenger, E., Sundaravel, S., Farahat, A. A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01911-7 · Cited by 22
“Initial pre-clinical investigations in mouse models of AML have demonstrated that these tool TF redistributors display on-target efficacy for eliminating leukemia 9 , warranting further development of next-generation versions of these agents pursuing superior pharmacokinetics.”
InfluentialSelf-citationDNA selection by the master transcription factor PU.1
Terrell, J. R., Taylor, S. J., Schneider, A. L., Lu, Y., Vernon, T. N., Xhani, S., Gumpper, R. H., Luo, M., Wilson, W. D., Steidl, U. G., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112671 · Cited by 25
Self-citationHong, J., Sui, P., Li, Y., Xu, K., Lee, J.-H., Wang, J., Shi, C., Zhang, P., Wingate, N., Noor, A., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.01.010 · Cited by 22
Harika, N. K., Germann, M. W., & Wilson, W. D. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201704563 · Cited by 18
Self-citationHuang, Z., Efthymiadou, A., Liang, N., Fan, R., & Treuter, E. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1230 · Cited by 19
“1 inhibition experiments, 5 M of DB2115 (MCE, HY124676A) inhibitor (38) was used overnight to block the DNA binding of PU.”
MethodA modular design for minor groove binding and recognition of mixed base pair sequences of DNA
Guo, P., Paul, A., Kumar, A., Harika, N. K., Wang, S., Farahat, A. A., Boykin, D. W., & Wilson, W. D. (2017) · Chemical Communications · doi:10.1039/c7cc06246j · Cited by 19
Self-citationPreleukemic and leukemic evolution at the stem cell level
Stauber, J., Greally, J. M., & Steidl, U. G. (2020) · Blood · doi:10.1182/blood.2019004397 · Cited by 22
Self-citationGuo, P., Farahat, A. A., Paul, A., Boykin, D. W., & Wilson, W. D. (2021) · Chemical Science · doi:10.1039/d1sc04720e · Cited by 16
Self-citationTranscription factors in the development and treatment of immune disorders
Drinan, S. D., Bass, J. I. F., & Bass, J. I. F. (2023) · Transcription · doi:10.1080/21541264.2023.2294623 · Cited by 17
“A recent study exemplified this by targeting the DNA minor grooves flanking PU.1 TF binding sites with small molecule inhibitors of the hetero-cyclic diamidine family for the treatment of acute myeloid leukemia (Figure 2c) [176].”
Paul, A., Nanjunda, R. K., & Wilson, W. D. (2023) · Current Protocols · doi:10.1002/cpz1.729 · Cited by 18
Self-citationTherapeutic Vulnerabilities of Transcription Factors in AML
Khan, I., Eklund, E. A., & Gartel, A. L. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0115 · Cited by 19
“1 has therapeutic benefit in leukemia (95) based on the observation that complete loss of PU.”
BackgroundTumdam, R., Kumar, A., Subbarao, N., & Balaji, B. (2018) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2018.1537301 · Cited by 14
Self-citationExtending the σ-Hole Motif for Sequence-Specific Recognition of the DNA Minor Groove
Guo, P., Farahat, A. A., Paul, A., Kumar, A., Boykin, D. W., & Wilson, W. D. (2020) · Biochemistry · doi:10.1021/acs.biochem.0c00090 · Cited by 14
Self-citationRahmati, A., Mafi, A., Soleymani, F., Aghdam, Z. B., Masihipour, N., Ghezelbash, B., Asemi, R., Aschner, M., Vakili, O., Homayoonfal, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1149187 · Cited by 16
Ninomiya, I., Koyama, A., Otsu, Y., Onodera, O., & Kanazawa, M. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1225504 · Cited by 24
“5 μg/ mice weighted 10 g (Antony-Debré et al., 2017) or vehicle solution (dimethyl sulfoxide, DMSO 11.”
BackgroundA Review of Cationic Arylfurans and Their Isosteres: Synthesis and Biological Importance
Ismail, M. A., El-Sayed, W. M., Shaaban, S., Abdelwahab, G. A., & Hamama, W. S. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666191029114830 · Cited by 13
Albrecht, A. V., Kim, H. M., & Poon, G. M. K. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky894 · Cited by 14
“1-expressing cells by flow cytometry (38).”
Self-citationXu, L., Francis, A., Turkistany, S. A., Shukla, D., Wong, A., Batista, C. R., & DeKoter, R. P. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.03.004 · Cited by 16
The roles of ETS transcription factors in liver fibrosis
Zhang, L.-Y., Tan, Y., Luo, X., Wu, J., & Ni, Y. (2022) · Human Cell · doi:10.1007/s13577-022-00848-5 · Cited by 12
“Moreover, DB1976 and DB1977 were able to eliminate the trans-activation of PU.1-dependent genes without detectable toxicity [77].”
BackgroundInfluentialLambert, M., Jambon, S., Bouhlel, M. A., Depauw, S., Vrevin, J., Blanck, S., Marot, G., Figeac, M., Preudhomme, C., Quesnel, B., et al. (2024) · HemaSphere · doi:10.1002/hem3.77 · Cited by 11
Self-citationHarika, N. K., & Wilson, W. D. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00647 · Cited by 11
Self-citationOgbonna, E. N., Paul, A., Terrell, J. R., Fang, Z., Chen, C., Poon, G. M. K., Boykin, D. W., & Wilson, W. D. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116861 · Cited by 12
Self-citationDissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia
Pingul, B. Y., Huang, H., Chen, Q., Alikarami, F., Zhang, Z., Qi, J., Bernt, K. M., Berger, S. L., Cao, Z., & Shi, J. (2022) · iScience · doi:10.1016/j.isci.2022.105139 · Cited by 11
“Peak overlap and differential analysis The Venn diagram of the IRF8 and PU.1 peaks comparison was generated using Bioconductor package ChIPpeakAnno (Zhu et al., 2010) function findOverlappingPeaks with mapped gap equal to 500bp. Metaplot and signal heatmap of the unique and overlapped enriched regions were generated u…”
ResultInfluentialX-ray Structure Characterization of the Selective Recognition of AT Base Pair Sequences
Ogbonna, E. N., Paul, A., Farahat, A. A., Terrell, J. R., Mineva, E., Ogbonna, V., Boykin, D. W., & Wilson, W. D. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.3c00002 · Cited by 12
Self-citationAnalyses of Genes Critical to Tumor Survival Reveal Potential ‘Supertargets’: Focus on Transcription
Chetverina, D., Vorobyeva, N. E., Győrffy, B., Shtil, A. A., & Erokhin, M. (2023) · Cancers · doi:10.3390/cancers15113042 · Cited by 10
“1 elimination was therapeutically beneficial in leukemia [21].”
BackgroundGu, S. (2024) · American Journal of Cancer Research · doi:10.62347/usaj2794 · Cited by 8
“Consistent with the results of a previous study [15], these two sequences successfully suppressed the expression of SPI1/PU.1 in BMDMs.”
ResultIntroduction and Classification of Leukemias
Brown, G. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0810-4_1 · Cited by 11
The roles of ubiquitination in AML
Wei, Z., Su, L., & Gao, S. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05415-y · Cited by 7
“Pharmacological inhibition of aberrant PU.1 has been proposed as a novel strategy to treat AML [115].”
Targeting transcription factor pu.1 for improving neurologic outcomes after spinal cord injury
Shi, Y., Zheng, M., Luo, Y., Li, J. J., Ouyang, F., Zhao, Y., Wang, J., Ma, Z., Meng, C., Bi, Y., et al. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1418615 · Cited by 6
DNA recognition by linear indole-biphenyl DNA minor groove ligands
Erlitzki, N., Farahat, A. A., Kumar, A., Boykin, D. W., & Poon, G. M. K. (2018) · Biophysical Chemistry · doi:10.1016/j.bpc.2018.11.004 · Cited by 6
Self-citationSadek, A., Petrier, M., Fourgeux, C., Braud, M., Gourain, V., Bouras, M., Poulain, C., Moumni, M., Roquilly, A., & Poschmann, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1731068 · Cited by 5
“Notably, PU.1 is pharmacologically targetable, and recent small-molecule inhibitors have been shown to modulate its activity in preclinical models (26).”
Sharma, R., Zhang, C., & Narendran, A. (2023) · Genes · doi:10.3390/genes14101916 · Cited by 5
“Previous reports have shown the involvement of PU.1 in KMT2A-rearranged and FLT3-mutated AML as well as B-ALL pathogenesis [15,17,18], and targeting PU.1 has been shown to be an effective therapeutic approach for AML treatment [30].”
BackgroundEpigallocatechin gallate regulates the myeloid-specific transcription factor PU.1 in macrophages
Karpurapu, M., Kakarala, K. K., Chung, S., Nie, Y., Koley, A., Dougherty, P. M., & Christman, J. W. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301904 · Cited by 5
Airway and parenchyma transcriptomics in a house dust mite model of experimental asthma
Tu, X., Gomez, H. M., Kim, R., Brown, A. C., de Jong, E., Galvão, I., Faiz, A., Bosco, A., Horvat, J. C., Hansbro, P. M., et al. (2023) · Respiratory Research · doi:10.1186/s12931-022-02298-x · Cited by 5
“DB1976 and DB2313 are small molecule SPI1 inhibitors that are heterocyclic diamidines that bind with high specificity to AT-rich sequences in the DNA minor groove that is selective for the SPI1 protein and thus competitively inhibit SPI1 binding [41, 42].”
BackgroundInfluentialSmall Sequence‐Sensitive Compounds for Specific Recognition of the G⋅C Base Pair in DNA Minor Groove
Farahat, A. A., Guo, P., Shoeib, H., Paul, A., Boykin, D. W., & Wilson, W. D. (2020) · Chemistry - A European Journal · doi:10.1002/chem.201904396 · Cited by 5
“In addition, diamidines have been shown to be excellent inhibitors of transcription factors (TFs) both in vitro [9,10] and in vivo [11,12].”
BackgroundSelf-citationPaul, A., Terrell, J. R., Farahat, A. A., Ogbonna, E. N., Kumar, A., Boykin, D. W., Neidle, S., & Wilson, W. D. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.4c00800 · Cited by 4
Self-citationRaczkowski, H. L., & DeKoter, R. P. (2021) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.1519 · Cited by 4
Barabino, S. M. L., Citterio, E., & Ronchi, A. E. (2021) · Cancers · doi:10.3390/cancers13153753 · Cited by 4
“1 DNA binding domain to reduce tumor burden [333].”
BackgroundRapid genome-wide introgression reveals fitness advantage of immigrant genotypesPreprint
Flanagan, B. A., Padhiar, A. A., Peng, F., Quraishi, S., Roth-Monzón, A. J., Gilani, F., Simonse, L., Maciejewski, M. F., Reid, N. M., Malinsky, M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.27.672692 · Cited by 7
“The small-molecule inhibitor db1976 blocks PU.1 activity ( 37 ), avoiding potential artifacts of gene editing.”
Identification of novel small molecule inhibitors of ETS transcription factors
Abdalla, S., Forghany, Z., Ma, J., Hollander, J. G., Nachane, R., Szuhai, K., Hogendoorn, P. C. W., ten Dijke, P., Shah, D., & Baker, D. A. (2025) · FEBS Letters · doi:10.1002/1873-3468.70040 · Cited by 3
“…kinases to impede tumour growth [1 – 5, 11 – 17], the clinical Approaches to identify inhibitors of the activity of either specific ETS factors [36,38,41] or ETS fusion proteins [37] have included computational chemistry methods and functional screens, which have yielded candidate molecules that…”
Single GC base pair recognition by a heterocyclic diamidine: structures, affinities, and dynamics
Ogbonna, E. N., Terrell, J. R., Paul, A., Farahat, A. A., Poon, G. M. K., Boykin, D. W., & Wilson, W. D. (2024) · RSC Advances · doi:10.1039/d4ra05957c · Cited by 3
Self-citationBender, A., Boydere, F., Jayavelu, A. K., Tibello, A., König, T., Aleth, H., zu Hörste, G. M., Vogl, T. J., & Rosenbauer, F. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00295-y · Cited by 6
“This question is important because PU.1 expression or activity is often impaired in AML, so that understanding how myeloid progenitors can survive PU.1 downregulation is of potential translational interest (Antony-Debré et al, 2017; Takei and Kobayashi, 2019).”
Tuerxun, K., Midtbö, K., Särndahl, E., Vorontsov, E., Karlsson, R., Persson, A., Kruse, R., & Eklund, D. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3a0421-216r · Cited by 5
Nong, Y., Guo, Y., Ou, Q., Gumpert, A. M., Tomlin, A. A., Zhu, X., & Bolli, R. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04561-7 · Cited by 3
“1 for AT-rich flanking sequences of the 5′-GGAA-3′ core and minimal effects on other E26 transformation-specific transcription factors [9, 28].”
BackgroundMethodCompound Shape and Substituent Effects in DNA Minor Groove Interactions
Wilson, W. D., & Paul, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-1313-5_29-1 · Cited by 3
Self-citationCompound Shape and Substituent Effects in DNA Minor Groove Interactions
Wilson, W. D., & Paul, A. (2023) · Springer eBooks · doi:10.1007/978-981-19-9776-1_29 · Cited by 3
Self-citationDissecting Dynamic and Hydration Contributions to Sequence-Dependent DNA Minor Groove Recognition
Ha, V. L., Erlitzki, N., Farahat, A. A., Kumar, A., Boykin, D. W., & Poon, G. M. K. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.08.013 · Cited by 6
Self-citationFarahat, A. A., Iwamoto, S., Roche, M. J., & Boykin, D. W. (2021) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.4353 · Cited by 3
Self-citationKim, H., Perovanovic, J., Shakya, A., Shen, Z., German, C. N., Ibarra, A., Jafek, J. L., Lin, N.-P., Evavold, B. D., Chou, D. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.02.06.937839 · Cited by 3
Self-citationSadalge, D., Clasman, J. R., Topal, S., Musser, D., Von der Porten, L., Wu, S., Schultz, S. E., Austin, W., Huang, D., Gao, Y.-D., et al. (2025) · doi:10.1101/2025.08.01.667454 · Cited by 2
Tufail, M., Zhang, J., He, C., Hu, J.-J., Liang, J., Wan, W., Huang, Y., Rao, Z., Wu, H., Jiang, C., et al. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111716 · Cited by 3
PLK2 Single Nucleotide Variant in Gastric Cancer Patients Affects miR-23b-5p Binding
Dominkuš, P. P., Mešić, A., & Hudler, P. (2022) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2022.22.e31 · Cited by 3
“1 inhibition by small-molecule inhibitors or RNA interference decreases the tumor burden and increased the survival of patients with acute myeloid leukemia [43].”
BackgroundExploiting a key transcriptional dependency: ZMYND8 and IRF8 in AML
Taylor, S. J., Sundaravel, S., & Steidl, U. G. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.013 · Cited by 2
Self-citationPSPC1 bridges cancer stemness and malignancy in acute myeloid leukemia
Yeh, H.-W., Lang, Y., Lee, H., & Jou, Y. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.02.006 · Cited by 1
Sleapnicov, N., Ha, S.-D., Zhong, S. J., Duchscher, J., Ezra, S., Li, S. S. ‐., & Kim, S. O. (2025) · Cancers · doi:10.3390/cancers17162684 · Cited by 1
“Previous studies on leukemia have shown that PU.1 can be either oncogenic [26,43,44] or tumor-suppressive [45,46] depending on the type of leukemia.”
InfluentialLiu, Z., Qin, Z., Li, H., Zhu, L., He, L., Chen, N., Zhu, D., Liu, Q., Dai, L., & Peng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02669-6 · Cited by 2
“41,42 In parallel, indirect strategies that modulate transcriptional dependency, including the use of epigenetic modulators that disrupt transcription factor-associated chromatin states and transcriptional CDK inhibitors that attenuate global RNA output, have been shown to be effective.”
Metadata
- Authors
- Antony-Debré, I., Paul, A., Leite, J., Mitchell, K., Kim, H. M., Carvajal, L. A., Todorova, T. I., Huang, K., Kumar, A., Farahat, A. A., Bartholdy, B., Narayanagari, S.-R., Chen, J., Ambesi-Impiombato, A., Ferrando, A. A., Mantzaris, I., Gavathiotis, E., Verma, A., Will, B., Boykin, D. W., Wilson, W. D., Poon, G. M. K., & Steidl, U.
- Affiliations
- Georgia State University (US)
- Albert Einstein College of Medicine (US)
- Mansoura University (EG)
- Columbia University (US)
- Corresponding author
- Steidl, Ulrich
- ORCID
- Paul, Ananya
- Mitchell, Kelly
- Kim, Hye Mi
- Carvajal, Luis A.
- Todorova, Tihomira I.
- Huang, Kenneth
- Kumar, Arvind
- Farahat, Abdelbasset A.
- Bartholdy, Boris
- Narayanagari, Swathi-Rao
- Chen, Jiahao
- Ambesi-Impiombato, Alberto
- Ferrando, Adolfo A.
- Mantzaris, Ioannis
- Gavathiotis, Evripidis
- Verma, Amit
- Will, Britta
- Wilson, W. David
- Poon, Gregory M.K.
- Steidl, Ulrich
- Venue
- Journal of Clinical Investigation
- Published
- 2017-10-30
- Volume
- 127
- Issue
- 12
- Pages
- 4297-4313
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5707147
- OpenAlex
- W2766367793
- Cited by
- 120
- References
- 58
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 10 · 2023: 16 · 2022: 19 · 2021: 11 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 2
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Leukemia & Lymphoma Society (6504-17)
- Henry and Marilyn Taub Foundation (Taub Foundation Grants Program for MDS Research)
- National Institutes of Health (R01CA217092)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- PU.1, acute myeloid leukemia, transcription factor inhibition, small molecule inhibitors, allosteric inhibition, DNA minor groove, chromatin binding, RNA interference, apoptosis, therapeutic target
- MeSH terms
- THP-1 Cells, Proto-Oncogene Protein Spi-1, Allosteric Regulation, Animals, Chromatin, Humans, Mice, Transgenic, Pentamidine, Proto-Oncogene Proteins, Leukemia, Myeloid, Acute, Trans-Activators, Apoptosis, Xenograft Model Antitumor Assays, RNA Interference, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.